Key Asset is LT-673, PARP Inhibitor for the Treatment of Genetically Defined Cancers Conference call and Webcast to Be Held Today at 5:00 p.m. ET NOVATO, Calif., Feb. 4 (HSMN NewsFeed) — BioMarin Pharma Inc. (Nasdaq: BMRN) announced today …
Biopharmaceuticals, Mergers & Acquisitions, Oncology
BioMarin Clinical, LEAD Therapeutics

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “BioMarin to Acquire LEAD Therapeutics”
Leave a Comment